Consider a scenario many manufacturers are now facing: your company reformulates a product line to remove synthetic dye. The new formulation passes all internal quality checks. It ships. Three weeks later, customer service starts receiving scattered complaints like stomach discomfort, an unfamiliar aftertaste, and a few reports mentioning “allergic reaction.” Individually, none of these cross a threshold. But taken together, across multiple reformulated SKUs, a pattern is forming.
Does your current system catch that pattern? For most food companies, the honest answer is no.
In pharmaceuticals, this type of scenario is anticipated by design. Every drug that reaches a patient has a post-market monitoring system watching what happens next. The pharmaceutical industry invests billions annually in pharmacovigilance—the structured discipline of detecting adverse events after products enter the market. The global pharmacovigilance market is projected to reach $13.5 billion by 2033.1 Adverse event reporting is mandatory. Pattern detection is systematic. Intervention happens before harm scales.
For food, which causes an estimated 48 million illnesses and 128,000 hospitalizations in the U.S. each year,2 we have no equivalent discipline for monitoring product performance after it reaches the people who consume it daily. We verify before shipping. We investigate after illness. The space in between is where harm accumulates undetected.
What Pharma Monitors That Food Does Not
The pharmaceutical model is built on a simple premise: what happens after a product reaches consumers is just as important as what happens before. Manufacturers are legally required to collect and report adverse events. The U.S. Food and Drug Administration’s (FDA’s) FDA Adverse Event Reporting System (FAERS) Database aggregates millions of reports. Structured frameworks (CIOMS, ICH E2D) provide standardized methods for assessing whether a product caused harm.3
Food has fragments of this concept but no cohesive system. Consumer complaint databases are company-specific and less often trended over time. CDC investigates outbreaks after illness clusters appear, typically weeks or months after initial exposure. FDA’s FAERS reporting system for food is voluntary. Notably, the 2006 Dietary Supplement and Nonprescription Drug Consumer Protection Act requires Serious Adverse Event reporting for supplements, yet no equivalent requirement exists for conventional food, despite food reaching far more consumers daily.4
The gap is not in knowledge or technology. It is in operational discipline. Most food companies have complaint data; few treat it as a monitoring system.
Looking for quick answers on food safety topics?
Try Ask FSM, our new smart AI search tool.
Ask FSM →
Why This Matters Now
Two forces are converging to make post-market product monitoring an urgent operational priority, not a theoretical nicety.
The Reformulation Wave
The Make America Healthy Again (MAHA) initiative is driving the most significant wave of food product reformulation in recent memory. FDA is tracking industry pledges to remove six petroleum-based dyes by the end of 2026.5 Major retailers are eliminating dozens of ingredients from private-label products. The Generally Recognized as Safe (GRAS) framework is under active reassessment, with ingredients long considered safe now facing renewed scrutiny.6
The scale matters. This is not one company changing one ingredient. This is thousands of products reformulating simultaneously, introducing new colorants, new preservative systems, new processing aids, and new allergen profiles into the market at the same time. Every substitution is a variable. New ingredients interact with existing formulations in ways that bench-scale testing may not fully predict. Consumer response to the food safety and quality of novel ingredients may not manifest until products are consumed repeatedly, in combination with other foods, by diverse populations with varying sensitivities.
Traditional quality release testing confirms that a product meets specification at the time of manufacture. It does not predict how that product will perform once it reaches millions of consumers over weeks and months. That requires a different kind of monitoring, and most companies do not have it.
The Regulator’s New Capability
At the 2026 Food and Drug Law Institute (FDLI) Annual Conference, FDA officials described the agency’s rapid integration of AI into regulatory operations. The agency launched Harmonized AI and Lifecycle Operations for Data (HALO), consolidating more than 40 internal data systems into a single platform. Its internal AI tool, Elsa 4.0, now supports inspectional planning, enforcement prioritization, and compliance review.7 FDA’s AI use cases grew 148 percent between fiscal years 2024 and 2025.8
What does this mean for food manufacturers? It means that when a local, state, or federal inspector arrives at your facility, they may already have access to complaints reported to the agency, recall correlations, and compliance history analyzed at a depth and speed that most internal quality teams cannot replicate. The question inspectors will increasingly ask is not just, “Do you have a food safety plan?” but rather, “Do you know how your products are performing in the market?”
Companies that can answer the latter question with data, trends, and risk assessment with documented monitoring will be in a fundamentally stronger position than those that cannot.
What Product Performance Monitoring Looks Like for Food
Pharmacovigilance thinking applied to food does not mean mandatory adverse event reporting or building pharmaceutical-grade surveillance infrastructure. It means treating your existing consumer feedback as a monitoring system rather than a complaint management function. It means asking: after reformulation, is this product performing as expected in the hands of consumers?
The operational shift is straightforward:
- Categorize consumer complaints by type, distinguishing health-related concerns (allergic reactions, illness, foreign material) from quality concerns (taste, texture, color, preference). Most companies already collect this data; few structure it for trend analysis.
- Correlate with formulation changes. When a product reformulates, create a monitoring window. Track whether complaint type, volume, or severity type shifts in the weeks and months following the change.
- Trend over time, not just by incident. A single complaint is a data point. Twenty complaints of the same type, concentrated in the same time period, correlated with the same ingredient change, is a pattern that demands investigation.
- Apply human validation before action. Data tools and AI-assisted trending can help teams identify which patterns warrant investigation and prioritize these by their risk to public health. Professionals must assess significance, determine root cause, and decide response.
- Document your monitoring activity—not for the purpose of reporting to regulators, but to demonstrate due diligence during inspections. A documented product performance monitoring program shows inspectors that you are actively watching, not waiting to be told there is a problem.
Practical Steps for Any Manufacturer
You do not need an enterprise AI platform to start. You need a process, frequency, and execution.
Start with what you have. Pull 12 months of customer complaints. Categorize them. Plot them by product and month. Do you see patterns? Now overlay your reformulation timeline or process changes timeline. Do complaint shifts correlate with ingredient or process changes? If you have not asked this question before, the answer will likely surprise you.
Also work to build a reformulation monitoring protocol. Every time a product reformulates—whether driven by MAHA initiatives, cost optimization, or supply chain substitution—establish a 90-day monitoring window. Define what you are watching for: complaint volume changes, new complaint categories, shifts in severity distribution, etc. Document what you find, even if the answer is “no change detected.” That documentation has value during audits as proof of risk assessment for your product in the market.
Adopt AI-assisted tools when volume demands it. As product portfolios grow and reformulation accelerates, manual complaint review becomes insufficient. AI-assisted classification can sort thousands of consumer contacts by severity and type, flagging the ones that warrant investigation. Multiple tools exist at varying complexity and price points. The barrier to adoption is not cost; it is recognizing when you have outgrown manual review.
Prepare for the inspector’s new question. Inspectors are increasingly data-savvy. Demonstrating that you actively monitor product performance, not just verify at release, positions your company as one that takes consumer health protection seriously. It is the difference between showing a stack of filed complaints and showing a trend analysis that proves you are watching, responding, and improving.
The Shift Ahead
Food safety has always prioritized what happens before a product ships: hazard analysis, preventive controls, supplier verification, batch release testing. These remain essential. But the reformulation wave driven by MAHA, combined with a regulator building AI capability to analyze market-level data, is creating a new expectation: that manufacturers also know what happens after. Pharma calls this pharmacovigilance. Food does not have a word for it yet, but the discipline—monitor, detect, assess, act—is the same. The companies that build it now will be the ones who are best prepared for inspections, fastest to identify emerging issues, and most trusted by the consumers who eat their products every day.
The tools exist. The data exists. The regulatory pressure is building. The only question is whether your company starts monitoring before something goes wrong, or after.
References
- Grand View Research. “Pharmacovigilance Market to Reach $13.5 Billion by 2033.” June 2026. https://www.grandviewresearch.com/press-release/global-pharmacovigilance-market.
- Centers for Disease Control and Prevention (CDC). “Estimates: Burden of Foodborne Illness in the United States.” March 19, 2025. https://www.cdc.gov/food-safety/php/data-research/foodborne-illness-burden/index.html.
- Anbil, P. “How Automation and AI Transform Pharmacovigilance.” Pharmaceutical Commerce. June 11, 2026. https://www.pharmaceuticalcommerce.com/view/how-automation-and-ai-can-transform-pharmacovigilance.
- 109th Congress. Dietary Supplement and Nonprescription Drug Consumer Protection Act. December 22, 2006. https://www.congress.gov/bill/109th-congress/senate-bill/3546.
- U.S. Food and Drug Administration (FDA). “Tracking Food Industry Pledges to Remove Petroleum-Based Food Dyes.” Current as of June 16, 2026. https://www.fda.gov/food/color-additives-information-consumers/tracking-food-industry-pledges-remove-petroleum-based-food-dyes.
- James, B., S. Jockel, and A. Spivey. “MAHA Strategy Report is Out: Key Takeaways for Food & Beverage Industry.” JD Supra. September 18, 2025. https://www.jdsupra.com/legalnews/maha-strategy-report-is-out-key-1313489/.
- Turow, R. “Report From FDLI Annual Meeting: FDA’s Expanding Use of AI—What Regulated Industry Should Know.” JD Supra. May 12, 2026. https://www.jdsupra.com/legalnews/report-from-fdli-annual-meeting-fda-s-8994263/.
- Wallace, C. “Federal Health Agencies Rapidly Scale AI Adoption, But Governance Lags Behind.” MDDI Online. June 12, 2026. https://www.mddionline.com/artificial-intelligence/federal-health-agencies-rapidly-scale-ai-adoption-but-governance-lags-behind.